Serum Abeta levels as predictors of conversion to mild cognitive impairment/Alzheimer disease in an ADAPT subcohort.
Recent evidence suggests an association of beta-amyloid (Abeta) with vascular risk factors and the medications to treat them, which could potentially obfuscate the usefulness of Abeta for prediction of mild cognitive impairment (MCI) or Alzheimer disease (AD). In a subcohort from the Alzheimer's Disease Anti-inflammatory Prevention Trial (enriched for family history of AD), we investigated whether systolic blood pressure, total cholesterol, triglycerides, serum creatinine, apolipoprotein E, and use of statins and antihypertensives influenced the predictive value of serum Abeta for MCI/AD during a 2-year period. We collected blood samples to quantify serum Abeta from cognitively normal participants (n = 203) at baseline and ascertained the outcome of MCI/AD (n = 24) for a period of approximately 2 years. In an unadjusted model, the lowest quartile of Abeta(1-42) (hazard ratio [HR] = 2.93, 95% CI [1.02-8.32], P = 0.04) and of the Abeta(1-42)/Abeta(1-40) ratio (HR = 3.53, 95% CI [1.24-10.07], P = 0.02), compared with the highest quartile, predicted conversion to MCI/AD, but no impact of Abeta(1-40) was observed. No relationship between nonsteroidal antiinflammatory drug interventions and Abeta on MCI/AD risk was evident. Once data were adjusted for potential confounders (age, sex, and education), vascular risk factors, and the medications listed above, the lowest quartiles of Abeta(1-42) (HR = 4.47, 95% CI [1.39-14.39], P = 0.01), and of the Abeta(1-42/)Abeta(1-40) ratio (HR 4.87, 95% CI [1.50-15.87], P = 0.01) became strong predictors of conversion to MCI/AD. In this subcohort of individuals at risk for AD, the association of Abeta with vascular risk factors and medications to treat these conditions did not interfere with Abeta's predictive value for MCI/AD.
Abdullah
Laila
L
Roskamp Institute, Sarasota, Florida 34243, USA. labdullah@rfdn.org
Luis
Cheryl
C
Paris
Daniel
D
Mouzon
Benoit
B
Ait-Ghezala
Ghania
G
Keegan
Andrew P
AP
Wang
Duolao
D
Crawford
Fiona
F
Mullan
Michael
M
D000368:Aged; D000544:Alzheimer Disease / Q000097:blood* / Q000175:diagnosis / Q000453:epidemiology; D016229:Amyloid beta-Peptides / Q000097:blood*; D015331:Cohort Studies; D003704:Dementia / Q000097:blood / Q000175:diagnosis; D005260:Female; D006801:Humans; D008297:Male; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D012307:Risk Factors
D016229:Amyloid beta-Peptides
Neurology. 1989 Sep;39(9):1159-65
2771064
Arch Neurol. 2007 Aug;64(8):1130-8
17698703
Neurology. 2009 Jun 2;72(22):1899-905
19386997
Gerontology. 2003 Nov-Dec;49(6):374-9
14624066
Ann Neurol. 2009 Apr;65(4):403-13
19296504
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S7-S14
18632005
Mol Med. 2000 May;6(5):430-9
10952022
Arch Intern Med. 2002 Oct 14;162(18):2046-52
12374512
Neurology. 2008 May 6;70(19):1664-71
18401021
World J Biol Psychiatry. 2005;6(2):85-97
16156481
J Psychiatr Res. 2008 Sep;42(11):946-55
18155247
Neurology. 1984 Jul;34(7):939-44
6610841
Arch Neurol. 2001 Dec;58(12):1985-92
11735772
CNS Spectr. 2008 Jan;13(1):45-53
18204414
Arch Neurol. 2008 Jul;65(7):896-905
18474729
Neurology. 2009 May 19;72(20):1727-34
19228584
Neurology. 2008 Jun 10;70(24):2291-8
18509093
Drug Discov Today. 2009 Mar;14(5-6):241-51
19135168
Arch Neurol. 2007 Mar;64(3):354-62
17353377
Neuroimage. 2009 Apr 15;45(3):645-55
19280686
Arch Clin Neuropsychol. 2006 Feb;21(2):151-60
16202560
Am J Geriatr Psychiatry. 2008 Nov;16(11):883-92
18978249
J Alzheimers Dis. 2004 Dec;6(6):585-9; discussion 673-81
15665398
Arch Neurol. 1999 Mar;56(3):303-8
10190820
Lancet Neurol. 2006 Aug;5(8):655-60
16857570
Neurology. 2008 Jan 1;70(1):17-24
18003940
J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):13-7
18931004
Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14052-7
18779561
Br J Clin Pharmacol. 2009 Jan;67(1):99-109
19006546
Mol Med. 2009 Mar-Apr;15(3-4):95-100
19081767
Neurology. 2007 May 22;68(21):1800-8
17460158
Ann Intern Med. 2002 Aug 6;137(3):149-55
12160362